1795 — Lotus Pharmaceutical Share Price
Last trade - 00:00- TWD48.13bn
- TWD100.25bn
- TWD20.51bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 7.88 | ||
| PEG Ratio (f) | 0.24 | ||
| EPS Growth (f) | 49.81% | ||
| Dividend Yield (f) | 2.71% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.98 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 146.82 | ||
| Price to Sales | 1.69 | ||
| EV to EBITDA | 11.15 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7.59% | ||
| Return on Equity | 16.86% | ||
| Operating Margin | 24.25% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | TWDm | 12,649.19 | 14,632.77 | 16,957.97 | 18,584.23 | 20,509.47 | 36,089.83 | 41,472.8 | 13.84% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +31.79 | +90.73 | +38.59 | +18.69 | -7.19 | -17.73 | +71.04 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lotus Pharmaceutical Co Ltd is a Taiwan-based company mainly engaged in the manufacture and sale of generic drugs. The products are mainly solid preparations such as tablets and capsules. The main products include oral anti-cancer drugs, cardiovascular disease drugs, central nervous system drugs, women's health products, osteoporosis drugs and mental disease drugs. The Company is also engaged in the drug research, development and clinical testing business, as well as the product licensing business. The Company mainly distributes products in Taiwan, South Korea, the United States, China mainland, Japan, Europe and Southeast Asia markets.
Directors
- Robert Wessman CHM (52)
- Yi-Lin Tien CFO
- Stanley Gu CEX
- Mingjun Xie CIO
- Petar Vazharov GMG
- Bjartur Shen DGM
- Manish Chawla DGM
- Zenon Zdunek DGM
- Wenzhong Chen OTH
- Amporn Charoensomsak DRC
- Arni Hardarson DRC
- Hirofumi Imai DRC (57)
- Thor Kristjansson DRC
- Benjamin Ku IND
- Han-Fei Lin IND
- Hjorleifur Palsson IND (58)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- June 30th, 1966
- Public Since
- December 13th, 2004
- No. of Shareholders
- 38,932
- No. of Employees
- 1,099
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Taiwan Stock Exchange
- Shares in Issue
- 265,914,754.75
- Address
- 17F, TAIPEI, 110
- Web
- https://www.lotuspharm.com.tw/
- Phone
- +886 227005908
- Auditors
- KPMG LLP
Latest News for 1795
Upcoming Events for 1795
October 2026 Lotus Pharmaceutical Co Ltd Corporate Sales Release
Q3 2026 Lotus Pharmaceutical Co Ltd Earnings Release
November 2026 Lotus Pharmaceutical Co Ltd Corporate Sales Release
December 2026 Lotus Pharmaceutical Co Ltd Corporate Sales Release
January 2027 Lotus Pharmaceutical Co Ltd Corporate Sales Release
February 2027 Lotus Pharmaceutical Co Ltd Corporate Sales Release
Q4 2026 Lotus Pharmaceutical Co Ltd Earnings Release
March 2027 Lotus Pharmaceutical Co Ltd Corporate Sales Release
Similar to 1795
Adimmune
Taiwan Stock Exchange
BORA PHARMACEUTICALS
Taiwan Stock Exchange
BRIM BIOTECHNOLOGY
Taiwan Stock Exchange
CALIWAY BIOPHARMACEUTICALS
Taiwan Stock Exchange
Cenra
Taiwan Stock Exchange
FAQ
As of Today at 03:51 UTC, shares in Lotus Pharmaceutical are trading at TWD181.00. This share price information is delayed by 15 minutes.
Shares in Lotus Pharmaceutical last closed at TWD181.00 and the price had moved by -36.56% over the past 365 days. In terms of relative price strength the Lotus Pharmaceutical share price has underperformed the FTSE Developed Asia Pacific Index by -53.66% over the past year.
The overall consensus recommendation for Lotus Pharmaceutical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Lotus Pharmaceutical dividend yield is 1.38% based on the trailing twelve month period.
Last year, Lotus Pharmaceutical paid a total dividend of TWD2.50, and it currently has a trailing dividend yield of 1.38%. We do not have any data on when Lotus Pharmaceutical is to next pay dividends.
We do not have data on when Lotus Pharmaceutical is to next pay dividends. The historic dividend yield on Lotus Pharmaceutical shares is currently 1.38%.
To buy shares in Lotus Pharmaceutical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of TWD181.00, shares in Lotus Pharmaceutical had a market capitalisation of TWD48.13bn.
Here are the trading details for Lotus Pharmaceutical:
- Country of listing: Taiwan
- Exchange: TAI
- Ticker Symbol: 1795
Based on an overall assessment of its quality, value and momentum Lotus Pharmaceutical is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Lotus Pharmaceutical is TWD365.57. That is 101.97% above the last closing price of TWD181.00.
Analysts covering Lotus Pharmaceutical currently have a consensus Earnings Per Share (EPS) forecast of TWD14.67 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lotus Pharmaceutical. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -24.51%.
As of the last closing price of TWD181.00, shares in Lotus Pharmaceutical were trading -18.43% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Lotus Pharmaceutical PE ratio based on its reported earnings over the past 12 months is 7.88. The shares last closed at TWD181.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Lotus Pharmaceutical's management team is headed by:
- Robert Wessman - CHM
- Yi-Lin Tien - CFO
- Stanley Gu - CEX
- Mingjun Xie - CIO
- Petar Vazharov - GMG
- Bjartur Shen - DGM
- Manish Chawla - DGM
- Zenon Zdunek - DGM
- Wenzhong Chen - OTH
- Amporn Charoensomsak - DRC
- Arni Hardarson - DRC
- Hirofumi Imai - DRC
- Thor Kristjansson - DRC
- Benjamin Ku - IND
- Han-Fei Lin - IND
- Hjorleifur Palsson - IND